Search

Author/Creator Rich, Benjamin

2. Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study. (26th December 2020)

Authors:
Gupta, Neeraj; Wang, Xiaohui; Offman, Elliot; Rich, Benjamin; Kerstein, David; Hanley, Michael; Diderichsen, Paul M.; Zhang, Pingkuan; Venkatakrishnan, Karthik
Journal:
CPT: pharmacometrics & systems pharmacology
Issue:
Volume 9:Number 12(2020)
Page Start:
718
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Population pharmacokinetics and exposure–response of trilaciclib in extensive‐stage small cell lung cancer and triple‐negative breast cancer. Issue 3 (19th October 2022)

Authors:
Li, Chao; Rich, Benjamin; Bullock, Julie M.; Barrière, Olivier; Marier, Jean‐Francois; Beelen, Andrew
Journal:
British journal of clinical pharmacology
Issue:
Volume 89:Issue 3(2023)
Page Start:
1067
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Issue 11 (29th March 2015)

Authors:
Bergthold, Guillaume; Bandopadhayay, Pratiti; Hoshida, Yujin; Ramkissoon, Shakti; Ramkissoon, Lori; Rich, Benjamin; Maire, Cecile L.; Paolella, Brenton R.; Schumacher, Steven E.; Tabak, Barbara; Ferrer-Luna, Ruben; Ozek, Memet; Sav, Aydin; Santagata, Sandro; Wen, Patrick Yung; Goumnerova, Liliana...
Journal:
Neuro-oncology
Issue:
Volume 17:Issue 11(2015:Nov.)
Page Start:
1486
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗